@article{835de97f01f04cb8b4071a3eb22447af,
title = "Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN-6 trial",
author = "Kolkailah, {Ahmed A.} and Ildiko Lingvay and Idit Dobrecky-Mery and Alona Aharonovich and David, {Jens Peter} and Cecilie Holse and S{\o}ren Rasmussen and McGuire, {Darren K.}",
note = "Funding Information: Dr Kolkailah was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number T32HL125247. The content is solely the responsibility of the authors and does not necessarily represent the official view of the National Institutes of Health. The authors thank the patients participating in the SUSTAIN‐6 trial, the investigators, all trial site staff and all Novo Nordisk A/S employees involved in the trial. We also thank Flavia Sciota, PhD and Ellen Robertshaw, PhD from AXON Communications for editorial assistance, funded by Novo Nordisk. Findings were reported as an oral presentation at the European Society of Cardiology Preventive Cardiology Congress in April 2022. ",
year = "2023",
month = apr,
doi = "10.1111/dom.14941",
language = "English (US)",
volume = "25",
pages = "1117--1120",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "4",
}